Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 115

1.

TCR Sequencing Reveals the Distinct Development of Fetal and Adult Human Vγ9Vδ2 T Cells.

Papadopoulou M, Tieppo P, McGovern N, Gosselin F, Chan JKY, Goetgeluk G, Dauby N, Cogan A, Donner C, Ginhoux F, Vandekerckhove B, Vermijlen D.

J Immunol. 2019 Sep 15;203(6):1468-1479. doi: 10.4049/jimmunol.1900592. Epub 2019 Aug 14.

PMID:
31413106
2.

TARP is an immunotherapeutic target in acute myeloid leukemia expressed in the leukemic stem cell compartment.

Depreter B, Weening KE, Vandepoele K, Essand M, De Moerloose B, Themeli M, Cloos J, Hanekamp D, Moors I, D' Hont I, Denys B, Uyttebroeck A, Van Damme A, Dedeken L, Snauwaert S, Goetgeluk G, De Munter S, Kerre T, Vandekerckhove B, Lammens T, Philippé J.

Haematologica. 2019 Aug 1. pii: haematol.2019.222612. doi: 10.3324/haematol.2019.222612. [Epub ahead of print]

3.

An accelerated, clinical-grade protocol to generate high yields of type 1-polarizing messenger RNA-loaded dendritic cells for cancer vaccination.

Brabants E, Heyns K, De Smet S, Devreker P, Ingels J, De Cabooter N, Debacker V, Dullaers M, VAN Meerbeeck JP, Vandekerckhove B, Vermaelen KY.

Cytotherapy. 2018 Sep;20(9):1164-1181. doi: 10.1016/j.jcyt.2018.06.006. Epub 2018 Aug 16.

PMID:
30122654
4.

Nanobody Based Dual Specific CARs.

De Munter S, Ingels J, Goetgeluk G, Bonte S, Pille M, Weening K, Kerre T, Abken H, Vandekerckhove B.

Int J Mol Sci. 2018 Jan 30;19(2). pii: E403. doi: 10.3390/ijms19020403.

5.

Delivering Type I Interferon to Dendritic Cells Empowers Tumor Eradication and Immune Combination Treatments.

Cauwels A, Van Lint S, Paul F, Garcin G, De Koker S, Van Parys A, Wueest T, Gerlo S, Van der Heyden J, Bordat Y, Catteeuw D, Rogge E, Verhee A, Vandekerckhove B, Kley N, Uzé G, Tavernier J.

Cancer Res. 2018 Jan 15;78(2):463-474. doi: 10.1158/0008-5472.CAN-17-1980. Epub 2017 Nov 29.

6.

The checkpoint for agonist selection precedes conventional selection in human thymus.

Verstichel G, Vermijlen D, Martens L, Goetgeluk G, Brouwer M, Thiault N, Van Caeneghem Y, De Munter S, Weening K, Bonte S, Leclercq G, Taghon T, Kerre T, Saeys Y, Van Dorpe J, Cheroutre H, Vandekerckhove B.

Sci Immunol. 2017 Feb 24;2(8). pii: eaah4232. doi: 10.1126/sciimmunol.aah4232.

7.

A Murine Intestinal Intraepithelial NKp46-Negative Innate Lymphoid Cell Population Characterized by Group 1 Properties.

Van Acker A, Gronke K, Biswas A, Martens L, Saeys Y, Filtjens J, Taveirne S, Van Ammel E, Kerre T, Matthys P, Taghon T, Vandekerckhove B, Plum J, Dunay IR, Diefenbach A, Leclercq G.

Cell Rep. 2017 May 16;19(7):1431-1443. doi: 10.1016/j.celrep.2017.04.068.

8.

A new transcript in the TCRB locus unveils the human ortholog of the mouse pre-Dß1 promoter.

Lethé B, Snauwaert S, Bricard O, Schröder D, Gomard T, Hames G, Muller C, Lurquin C, Gauthy E, Essaghir A, Vandekerckhove B, Coulie PG.

Immun Inflamm Dis. 2017 Sep;5(3):346-354. doi: 10.1002/iid3.172. Epub 2017 May 15.

9.

Antigen receptor-redirected T cells derived from hematopoietic precursor cells lack expression of the endogenous TCR/CD3 receptor and exhibit specific antitumor capacities.

Van Caeneghem Y, De Munter S, Tieppo P, Goetgeluk G, Weening K, Verstichel G, Bonte S, Taghon T, Leclercq G, Kerre T, Debets R, Vermijlen D, Abken H, Vandekerckhove B.

Oncoimmunology. 2017 Jan 19;6(3):e1283460. doi: 10.1080/2162402X.2017.1283460. eCollection 2017.

10.

The Ly49E Receptor Inhibits the Immune Control of Acute Trypanosoma cruzi Infection.

Filtjens J, Coltel N, Cencig S, Taveirne S, Van Ammel E, Van Acker A, Kerre T, Matthys P, Taghon T, Vandekerckhove B, Carlier Y, Truyens C, Leclercq G.

Front Immunol. 2016 Nov 10;7:472. eCollection 2016.

11.

The role of Ly49E receptor expression on murine intraepithelial lymphocytes in intestinal cancer development and progression.

Van Acker A, Louagie E, Filtjens J, Taveirne S, Van Ammel E, Kerre T, Elewaut D, Taghon T, Vandekerckhove B, Plum J, Leclercq G.

Cancer Immunol Immunother. 2016 Nov;65(11):1365-1375. Epub 2016 Sep 1.

PMID:
27585789
12.

Expression of the inhibitory Ly49E receptor is not critically involved in the immune response against cutaneous, pulmonary or liver tumours.

Filtjens J, Keirsse J, Van Ammel E, Taveirne S, Van Acker A, Kerre T, Taghon T, Vandekerckhove B, Plum J, Van Ginderachter JA, Leclercq G.

Sci Rep. 2016 Jul 29;6:30564. doi: 10.1038/srep30564.

13.

Gene Correction of iPSCs from a Wiskott-Aldrich Syndrome Patient Normalizes the Lymphoid Developmental and Functional Defects.

Laskowski TJ, Van Caeneghem Y, Pourebrahim R, Ma C, Ni Z, Garate Z, Crane AM, Li XS, Liao W, Gonzalez-Garay M, Segovia JC, Paschon DE, Rebar EJ, Holmes MC, Kaufman D, Vandekerckhove B, Davis BR.

Stem Cell Reports. 2016 Aug 9;7(2):139-48. doi: 10.1016/j.stemcr.2016.06.003. Epub 2016 Jul 7.

14.

Radiation Sensitivity of Human CD34(+) Cells Versus Peripheral Blood T Lymphocytes of Newborns and Adults: DNA Repair and Mutagenic Effects.

Vandevoorde C, Vral A, Vandekerckhove B, Philippé J, Thierens H.

Radiat Res. 2016 Jun;185(6):580-90. doi: 10.1667/RR14109.1. Epub 2016 May 19.

PMID:
27195608
15.

GATA3 induces human T-cell commitment by restraining Notch activity and repressing NK-cell fate.

Van de Walle I, Dolens AC, Durinck K, De Mulder K, Van Loocke W, Damle S, Waegemans E, De Medts J, Velghe I, De Smedt M, Vandekerckhove B, Kerre T, Plum J, Leclercq G, Rothenberg EV, Van Vlierberghe P, Speleman F, Taghon T.

Nat Commun. 2016 Apr 6;7:11171. doi: 10.1038/ncomms11171.

16.

Pluripotent stem cell based gene therapy for hematological diseases.

Vanhee S, Vandekerckhove B.

Crit Rev Oncol Hematol. 2016 Jan;97:238-46. doi: 10.1016/j.critrevonc.2015.08.022. Epub 2015 Sep 14. Review.

PMID:
26381313
17.

Humanized Mice to Study Human T Cell Development.

Bonte S, Snauwaert S, Vanhee S, Dolens AC, Taghon T, Vandekerckhove B, Kerre T.

Methods Mol Biol. 2016;1323:253-72. doi: 10.1007/978-1-4939-2809-5_21.

PMID:
26294414
18.

Notch3 activation is sufficient but not required for inducing human T-lineage specification.

Waegemans E, Van de Walle I, De Medts J, De Smedt M, Kerre T, Vandekerckhove B, Leclercq G, Wang T, Plum J, Taghon T.

J Immunol. 2014 Dec 15;193(12):5997-6004. doi: 10.4049/jimmunol.1400764. Epub 2014 Nov 7.

19.

In vitro human embryonic stem cell hematopoiesis mimics MYB-independent yolk sac hematopoiesis.

Vanhee S, De Mulder K, Van Caeneghem Y, Verstichel G, Van Roy N, Menten B, Velghe I, Philippé J, De Bleser D, Lambrecht BN, Taghon T, Leclercq G, Kerre T, Vandekerckhove B.

Haematologica. 2015 Feb;100(2):157-66. doi: 10.3324/haematol.2014.112144. Epub 2014 Nov 7.

20.

Ly49E expression on CD8αα-expressing intestinal intraepithelial lymphocytes plays no detectable role in the development and progression of experimentally induced inflammatory bowel diseases.

Van Acker A, Filtjens J, Van Welden S, Taveirne S, Van Ammel E, Vanhees M, Devisscher L, Kerre T, Taghon T, Vandekerckhove B, Plum J, Leclercq G.

PLoS One. 2014 Oct 13;9(10):e110015. doi: 10.1371/journal.pone.0110015. eCollection 2014. Erratum in: PLoS One. 2015;10(4):e0124464.

21.

Contribution of the Ly49E natural killer receptor in the immune response to Plasmodium berghei infection and control of hepatic parasite development.

Filtjens J, Foquet L, Taveirne S, Van Ammel E, Vanhees M, Van Acker A, Kerre T, Taghon T, Vandekerckhove B, Plum J, Van den Steen PE, Leclercq G.

PLoS One. 2014 Jan 30;9(1):e87463. doi: 10.1371/journal.pone.0087463. eCollection 2014.

22.

In vitro generation of mature, naive antigen-specific CD8(+) T cells with a single T-cell receptor by agonist selection.

Snauwaert S, Verstichel G, Bonte S, Goetgeluk G, Vanhee S, Van Caeneghem Y, De Mulder K, Heirman C, Stauss H, Heemskerk MH, Taghon T, Leclercq G, Plum J, Langerak AW, Thielemans K, Kerre T, Vandekerckhove B.

Leukemia. 2014 Apr;28(4):830-41. doi: 10.1038/leu.2013.285. Epub 2013 Oct 4.

PMID:
24091848
23.

Specific Notch receptor-ligand interactions control human TCR-αβ/γδ development by inducing differential Notch signal strength.

Van de Walle I, Waegemans E, De Medts J, De Smet G, De Smedt M, Snauwaert S, Vandekerckhove B, Kerre T, Leclercq G, Plum J, Gridley T, Wang T, Koch U, Radtke F, Taghon T.

J Exp Med. 2013 Apr 8;210(4):683-97. doi: 10.1084/jem.20121798. Epub 2013 Mar 25.

24.

Can immunotherapy specifically target acute myeloid leukemic stem cells?

Snauwaert S, Vandekerckhove B, Kerre T.

Oncoimmunology. 2013 Feb 1;2(2):e22943.

25.

Abundant stage-dependent Ly49E expression by liver NK cells is not essential for their differentiation and function.

Filtjens J, Taveirne S, Van Acker A, Van Ammel E, Vanhees M, Kerre T, Taghon T, Vandekerckhove B, Plum J, Leclercq G.

J Leukoc Biol. 2013 May;93(5):699-711. doi: 10.1189/jlb.0812378. Epub 2013 Mar 8.

PMID:
23475576
26.

Differential Ly49e expression pathways in resting versus TCR-activated intraepithelial γδ T cells.

Van Den Broeck T, Van Ammel E, Delforche M, Taveirne S, Kerre T, Vandekerckhove B, Taghon T, Plum J, Leclercq G.

J Immunol. 2013 Mar 1;190(5):1982-90. doi: 10.4049/jimmunol.1200354. Epub 2013 Jan 21.

27.

Recommendations in the event of a suspected transfusion-related acute lung injury (TRALI).

Van der Linden P, Lambermont M, Dierick A, Hübner R, Benoit Y, De Backer D, De Paep R, Ferrant A, Latinne D, Muylle L, Selleslag D, Szabo B, Thomas I, Vandekerckhove B, Deneys V; Working Group of the Superior Health Council.

Acta Clin Belg. 2012 May-Jun;67(3):201-8.

PMID:
22897069
28.

RHAMM/HMMR (CD168) is not an ideal target antigen for immunotherapy of acute myeloid leukemia.

Snauwaert S, Vanhee S, Goetgeluk G, Verstichel G, Van Caeneghem Y, Velghe I, Philippé J, Berneman ZN, Plum J, Taghon T, Leclercq G, Thielemans K, Kerre T, Vandekerckhove B.

Haematologica. 2012 Oct;97(10):1539-47. doi: 10.3324/haematol.2012.065581. Epub 2012 Apr 24.

29.

Prosthetic inlay resurfacing for the treatment of focal, full thickness cartilage defects of the femoral condyle: a bridge between biologics and conventional arthroplasty.

Bollars P, Bosquet M, Vandekerckhove B, Hardeman F, Bellemans J.

Knee Surg Sports Traumatol Arthrosc. 2012 Sep;20(9):1753-9. doi: 10.1007/s00167-011-1757-9. Epub 2011 Nov 11.

PMID:
22076054
30.

Notch induces human T-cell receptor γδ+ thymocytes to differentiate along a parallel, highly proliferative and bipotent CD4 CD8 double-positive pathway.

Van Coppernolle S, Vanhee S, Verstichel G, Snauwaert S, van der Spek A, Velghe I, Sinnesael M, Heemskerk MH, Taghon T, Leclercq G, Plum J, Langerak AW, Kerre T, Vandekerckhove B.

Leukemia. 2012 Jan;26(1):127-38. doi: 10.1038/leu.2011.324. Epub 2011 Nov 4.

PMID:
22051534
31.

Inhibitory receptors specific for MHC class I educate murine NK cells but not CD8αα intestinal intraepithelial T lymphocytes.

Taveirne S, Filtjens J, Van Ammel E, De Colvenaer V, Kerre T, Taghon T, Vandekerckhove B, Plum J, Held W, Leclercq G.

Blood. 2011 Jul 14;118(2):339-47. doi: 10.1182/blood-2011-01-331124. Epub 2011 May 25.

32.

Langerhans cells are not required for epidermal Vgamma3 T cell homeostasis and function.

Taveirne S, De Colvenaer V, Van Den Broeck T, Van Ammel E, Bennett CL, Taghon T, Vandekerckhove B, Plum J, Clausen BE, Kaplan DH, Leclercq G.

J Leukoc Biol. 2011 Jul;90(1):61-8. doi: 10.1189/jlb.1010581. Epub 2011 Apr 12.

33.

A double-blind randomized controlled trial (RCT) of Titanium-13Zirconium versus Titanium Grade IV small-diameter bone level implants in edentulous mandibles--results from a 1-year observation period.

Al-Nawas B, Brägger U, Meijer HJ, Naert I, Persson R, Perucchi A, Quirynen M, Raghoebar GM, Reichert TE, Romeo E, Santing HJ, Schimmel M, Storelli S, ten Bruggenkate C, Vandekerckhove B, Wagner W, Wismeijer D, Müller F.

Clin Implant Dent Relat Res. 2012 Dec;14(6):896-904. doi: 10.1111/j.1708-8208.2010.00324.x. Epub 2011 Mar 17.

PMID:
21414131
34.

Jagged2 acts as a Delta-like Notch ligand during early hematopoietic cell fate decisions.

Van de Walle I, De Smet G, Gärtner M, De Smedt M, Waegemans E, Vandekerckhove B, Leclercq G, Plum J, Aster JC, Bernstein ID, Guidos CJ, Kyewski B, Taghon T.

Blood. 2011 Apr 28;117(17):4449-59. doi: 10.1182/blood-2010-06-290049. Epub 2011 Mar 3.

35.

T-lymphoid differentiation potential measured in vitro is higher in CD34+CD38-/lo hematopoietic stem cells from umbilical cord blood than from bone marrow and is an intrinsic property of the cells.

De Smedt M, Leclercq G, Vandekerckhove B, Kerre T, Taghon T, Plum J.

Haematologica. 2011 May;96(5):646-54. doi: 10.3324/haematol.2010.036343. Epub 2011 Feb 17.

36.

CD27-deficient mice show normal NK-cell differentiation but impaired function upon stimulation.

De Colvenaer V, Taveirne S, Delforche M, De Smedt M, Vandekerckhove B, Taghon T, Boon L, Plum J, Leclercq G.

Immunol Cell Biol. 2011 Oct;89(7):803-11. doi: 10.1038/icb.2010.171. Epub 2011 Feb 1.

PMID:
21283110
37.

In vitro generation of immune cells from pluripotent stem cells.

Vandekerckhove B, Vanhee S, Van Coppernolle S, Snauwaert S, Velghe I, Taghon T, Leclercq G, Kerre T, Plum J.

Front Biosci (Landmark Ed). 2011 Jan 1;16:1488-504. Review.

PMID:
21196243
38.

Continuous CD27 triggering in vivo strongly reduces NK cell numbers.

De Colvenaer V, Taveirne S, Hamann J, de Bruin AM, De Smedt M, Taghon T, Vandekerckhove B, Plum J, van Lier R, Leclercq G.

Eur J Immunol. 2010 Apr;40(4):1107-17. doi: 10.1002/eji.200939251.

39.

Clinical reliability of non-organoleptic oral malodour measurements.

Vandekerckhove B, Van den Velde S, De Smit M, Dadamio J, Teughels W, Van Tornout M, Quirynen M.

J Clin Periodontol. 2009 Nov;36(11):964-9. doi: 10.1111/j.1600-051X.2009.01473.x.

PMID:
19843192
40.

Characteristics of 2000 patients who visited a halitosis clinic.

Quirynen M, Dadamio J, Van den Velde S, De Smit M, Dekeyser C, Van Tornout M, Vandekerckhove B.

J Clin Periodontol. 2009 Nov;36(11):970-5. doi: 10.1111/j.1600-051X.2009.01478.x. Epub 2009 Oct 6.

PMID:
19811581
41.

Functionally mature CD4 and CD8 TCRalphabeta cells are generated in OP9-DL1 cultures from human CD34+ hematopoietic cells.

Van Coppernolle S, Verstichel G, Timmermans F, Velghe I, Vermijlen D, De Smedt M, Leclercq G, Plum J, Taghon T, Vandekerckhove B, Kerre T.

J Immunol. 2009 Oct 15;183(8):4859-70. doi: 10.4049/jimmunol.0900714.

42.

Generation of T cells from human embryonic stem cell-derived hematopoietic zones.

Timmermans F, Velghe I, Vanwalleghem L, De Smedt M, Van Coppernolle S, Taghon T, Moore HD, Leclercq G, Langerak AW, Kerre T, Plum J, Vandekerckhove B.

J Immunol. 2009 Jun 1;182(11):6879-88. doi: 10.4049/jimmunol.0803670.

43.

Guidelines for the use of fresh frozen plasma.

De Backer D, Vandekerckhove B, Stanworth S, Williamson L, Hermans C, Van der Linden P, Hübner R, Baele P, Jochmans K, Ferrant A, Lambermont M, Muylle L, Toungouz M.

Acta Clin Belg. 2008 Nov-Dec;63(6):381-90.

PMID:
19170354
44.

Endothelial progenitor cells: identity defined?

Timmermans F, Plum J, Yöder MC, Ingram DA, Vandekerckhove B, Case J.

J Cell Mol Med. 2009 Jan;13(1):87-102. doi: 10.1111/j.1582-4934.2008.00598.x. Review.

45.

An early decrease in Notch activation is required for human TCR-alphabeta lineage differentiation at the expense of TCR-gammadelta T cells.

Van de Walle I, De Smet G, De Smedt M, Vandekerckhove B, Leclercq G, Plum J, Taghon T.

Blood. 2009 Mar 26;113(13):2988-98. doi: 10.1182/blood-2008-06-164871. Epub 2008 Dec 3.

46.

Notch signaling is required for proliferation but not for differentiation at a well-defined beta-selection checkpoint during human T-cell development.

Taghon T, Van de Walle I, De Smet G, De Smedt M, Leclercq G, Vandekerckhove B, Plum J.

Blood. 2009 Apr 2;113(14):3254-63. doi: 10.1182/blood-2008-07-168906. Epub 2008 Oct 23.

47.

Human intrathymic development: a selective approach.

Plum J, De Smedt M, Leclercq G, Taghon T, Kerre T, Vandekerckhove B.

Semin Immunopathol. 2008 Dec;30(4):411-23. doi: 10.1007/s00281-008-0135-2. Epub 2008 Oct 17. Review.

PMID:
18925396
48.

Ly49E-dependent inhibition of natural killer cells by urokinase plasminogen activator.

Van Den Broeck T, Stevenaert F, Taveirne S, Debacker V, Vangestel C, Vandekerckhove B, Taghon T, Matthys P, Plum J, Held W, Dewerchin M, Yokoyama WM, Leclercq G.

Blood. 2008 Dec 15;112(13):5046-51. doi: 10.1182/blood-2008-06-164350. Epub 2008 Sep 10.

49.

Multicentre, prospective, open study to evaluate the safety and efficacy of hylan G-F 20 in knee osteoarthritis subjects presenting with pain following arthroscopic meniscectomy.

Huskin JP, Vandekerckhove B, Delincé P, Verdonk R, Dubuc JE, Willems S, Hardy P, Blanco FJ, Charrois O, Handelberg F.

Knee Surg Sports Traumatol Arthrosc. 2008 Aug;16(8):747-52. doi: 10.1007/s00167-008-0556-4. Epub 2008 Jun 7.

50.

Time-dependent effects on coronary remodeling and epicardial conductance after intracoronary injection of enriched hematopoietic bone marrow stem cells in patients with previous myocardial infarction.

Vanderheyden M, Vercauteren S, Mansour S, Delrue L, Vandekerckhove B, Heyndrickx GR, Van Haute I, De Bruyne B, Timmermans F, Wijns W, Bartunek J.

Cell Transplant. 2007;16(9):919-25.

PMID:
18293890

Supplemental Content

Loading ...
Support Center